Evidence mapPaperPMID 39558979Full record

ArticleFrontiers in endocrinology2024

Predictive value of bone metabolism markers in the progression of diabetic kidney disease: a cross-sectional study.

Yi Kang, Qian Jin, Mengqi Zhou, Zirong Li, Huijuan Zheng, Danwen Li, Weijing Liu, Yaoxian Wang, Jie Lv

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi Kang *Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Qian Jin *Graduate School of Beijing University of Chinese Medicine, Beijing, China.
Mengqi Zhou *Department of Traditional Chinese Medicine, Beijing Puren Hospital, Beijing, China.
Zirong LiGraduate School of Beijing University of Chinese Medicine, Beijing, China.
Huijuan ZhengDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Danwen LiDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Weijing LiuDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Yaoxian WangDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Jie LvDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to investigate the relationship between bone metabolism markers, including serum klotho, fibroblast growth factor 23 (FGF23), 25(OH)D3, iPTH, calcium (Ca), and PHOS and the progression of diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM). Additionally, the predictive value of these markers for DKD progression was evaluated. Methods: This study involved 126 patients with T2DM between May 2021 and March 2023. DKD staging was assessed based on urinary protein excretion rates and estimated glomerular filtration rate (eGFR). The study evaluated serum concentrations of klotho, FGF23, 25(OH)D3, iPTH, Ca and PHOS across various stages and examined their relationships with clinical parameters. Receiver operating characteristic (ROC) curve analysis was utilized to determine the predictive accuracy of these bone metabolism markers for DKD. Multivariate linear and logistic regression analyses identified risk factors linked to DKD severity. Results: Among the 126 participants, 30 had non-DKD with normal proteinuria, while 96 had DKD, categorized as 31 with stage III DKD (microproteinuria), 34 with stage IV DKD, and 31 with stage V DKD (massive proteinuria). With advancing DKD from stage III to V, levels of klotho, 25(OH)D3, and Ca decreased significantly, whereas FGF23, iPTH and PHOS levels increased markedly. Klotho is significantly positively correlated with eGFR ( Conclusion: Bone metabolism markers, such as klotho, FGF23, 25(OH)D3, iPTH, Ca and PHOS are intricately linked to DKD progression and may function as valuable predictive biomarkers.

Indexed as

BiomarkersDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionFibroblast Growth Factor-23Klotho ProteinsAdultAgedBone and BonesCalciumCross-Sectional StudiesFemaleFibroblast Growth FactorsGlomerular Filtration RateGlucuronidaseHumansBiomarkersCalciumFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseKlotho ProteinsParathyroid Hormonebone metabolism markersdiabetic kidney diseasepredictive valueprogressiontype 2 diabetes mellitus

Identifiers

PMID39558979
PMCPMC11570274

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.